SE446666B - Forfarande och anordning for bestemning av en rorlig komponent i ett i en behallare infort vetskeprov, varvid denna komponent reagerar med immobiliserad komponent applicerad pa en matris med fenliknande utsprang - Google Patents
Forfarande och anordning for bestemning av en rorlig komponent i ett i en behallare infort vetskeprov, varvid denna komponent reagerar med immobiliserad komponent applicerad pa en matris med fenliknande utsprangInfo
- Publication number
- SE446666B SE446666B SE7806400A SE7806400A SE446666B SE 446666 B SE446666 B SE 446666B SE 7806400 A SE7806400 A SE 7806400A SE 7806400 A SE7806400 A SE 7806400A SE 446666 B SE446666 B SE 446666B
- Authority
- SE
- Sweden
- Prior art keywords
- component
- matrix
- reaction
- fins
- container
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 44
- 239000007788 liquid Substances 0.000 title claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 114
- 239000000427 antigen Substances 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 22
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 238000009792 diffusion process Methods 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 238000009739 binding Methods 0.000 claims description 12
- 230000027455 binding Effects 0.000 claims description 10
- 230000000984 immunochemical effect Effects 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 7
- 238000000465 moulding Methods 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 description 134
- 239000007790 solid phase Substances 0.000 description 37
- 239000000523 sample Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 22
- 230000008901 benefit Effects 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 239000012295 chemical reaction liquid Substances 0.000 description 14
- 239000000376 reactant Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000003746 solid phase reaction Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000008416 Ferritin Methods 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 102000008857 Ferritin Human genes 0.000 description 5
- 108050000784 Ferritin Proteins 0.000 description 5
- 229960005156 digoxin Drugs 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 229940034208 thyroxine Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 4
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920000193 polymethacrylate Polymers 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 239000008057 potassium phosphate buffer Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- -1 vapors Substances 0.000 description 3
- JOJYUFGTMHSFEE-YONYXQDTSA-M Cytarabine ocfosphate Chemical compound [Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JOJYUFGTMHSFEE-YONYXQDTSA-M 0.000 description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006149 azo coupling reaction Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80548077A | 1977-06-10 | 1977-06-10 | |
| US05/805,431 US4197287A (en) | 1977-06-10 | 1977-06-10 | Method and apparatus for performing in nitro clinical diagnostic tests using a solid phase assay system having special utility for use with automatic pipetting equipment |
| US05/905,552 US4225575A (en) | 1978-05-15 | 1978-05-15 | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7806400L SE7806400L (sv) | 1978-12-11 |
| SE446666B true SE446666B (sv) | 1986-09-29 |
Family
ID=27420015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7806400A SE446666B (sv) | 1977-06-10 | 1978-05-31 | Forfarande och anordning for bestemning av en rorlig komponent i ett i en behallare infort vetskeprov, varvid denna komponent reagerar med immobiliserad komponent applicerad pa en matris med fenliknande utsprang |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS5463796A (enrdf_load_stackoverflow) |
| AU (1) | AU521002B2 (enrdf_load_stackoverflow) |
| CA (1) | CA1109791A (enrdf_load_stackoverflow) |
| DE (1) | DE2824742A1 (enrdf_load_stackoverflow) |
| DK (1) | DK257378A (enrdf_load_stackoverflow) |
| FR (1) | FR2394088A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1584129A (enrdf_load_stackoverflow) |
| SE (1) | SE446666B (enrdf_load_stackoverflow) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4305924A (en) * | 1979-08-08 | 1981-12-15 | Ventrex Laboratories, Inc. | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system |
| US4378344A (en) * | 1979-09-28 | 1983-03-29 | Ventrex Laboratories, Inc. | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system |
| ZA806976B (en) * | 1979-11-13 | 1981-10-28 | Ventrex Lab Inc | Method and apparatus for carrying out solid phase in vitro diagnostic assays |
| FI61965C (fi) * | 1980-01-17 | 1982-10-11 | Suovaniemi Finnpipette | Foerfarande foer detektering av hemoglobin i avfoering |
| GB2079181B (en) * | 1980-05-27 | 1983-12-21 | Secr Social Service Brit | Support means for chemical analysis |
| EP0146654A3 (en) * | 1980-06-20 | 1986-08-20 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
| EP0042755B1 (en) * | 1980-06-20 | 1988-08-24 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
| EP0085276A1 (de) * | 1981-12-10 | 1983-08-10 | Greiner Electronics Ag | Verfahren zur immunchemischen Bestimmung einer Substanz |
| JPS58189558A (ja) * | 1982-04-28 | 1983-11-05 | Mochida Pharmaceut Co Ltd | 免疫学的測定用容器 |
| AU529210B3 (en) * | 1983-02-02 | 1983-04-14 | Australian Monoclonal Development Pty. Ltd. | Monoclonal antibody in occult blood diagnosis |
| GB8406752D0 (en) * | 1984-03-15 | 1984-04-18 | Unilever Plc | Chemical and clinical tests |
| US4657869A (en) * | 1984-05-18 | 1987-04-14 | E. I. Du Pont De Nemours And Company | Self-contained device for carrying out specific binding assays |
| FI930440A0 (fi) * | 1993-02-01 | 1993-02-01 | Labsystems Oy | Bestaemningsfoerfarande |
| EP0681700B1 (en) | 1993-02-01 | 2001-11-21 | Thermo Labsystems Oy | Method for magnetic particle specific binding assay |
| FI944938A0 (fi) * | 1994-10-20 | 1994-10-20 | Labsystems Oy | Foerflyttningsanordning |
| FI944937A0 (fi) | 1994-10-20 | 1994-10-20 | Labsystems Oy | Separeringsanordning |
| FI944940A0 (fi) * | 1994-10-20 | 1994-10-20 | Labsystems Oy | Tvaofasigt separeringsfoerfarande |
| FI944939A0 (fi) * | 1994-10-20 | 1994-10-20 | Labsystems Oy | Foerfarande foer separering av partiklar |
| SE0002820L (sv) * | 2000-08-04 | 2002-02-05 | Jordanian Pharmaceutical Mfg & | Medicinskt kit |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3826619A (en) * | 1971-12-21 | 1974-07-30 | Abbott Lab | Test apparatus for direct radioimmuno-assay for antigens and their antibodies |
| CH583422A5 (enrdf_load_stackoverflow) * | 1972-01-25 | 1976-12-31 | Hoffmann La Roche | |
| DE2438436B2 (de) * | 1974-08-09 | 1979-11-29 | Boehringer Mannheim Gmbh, 6800 Mannheim | Formgegenstand mit enzymatisch aktiver Oberfläche und Verfahren zu seiner Herstellung |
| US4020151A (en) * | 1976-02-17 | 1977-04-26 | International Diagnostic Technology, Inc. | Method for quantitation of antigens or antibodies on a solid surface |
| FI54842C (fi) * | 1977-01-14 | 1979-03-12 | Suovaniemi Finnpipette | Formstycke i anordningar foer immunitetsbestaemningar och enzymreaktioner |
| US4116638A (en) * | 1977-03-03 | 1978-09-26 | Warner-Lambert Company | Immunoassay device |
-
1978
- 1978-05-30 GB GB24400/78A patent/GB1584129A/en not_active Expired
- 1978-05-31 SE SE7806400A patent/SE446666B/sv not_active IP Right Cessation
- 1978-06-06 DE DE19782824742 patent/DE2824742A1/de active Granted
- 1978-06-08 AU AU36927/78A patent/AU521002B2/en not_active Expired
- 1978-06-08 FR FR787817166A patent/FR2394088A1/fr active Granted
- 1978-06-09 JP JP6972478A patent/JPS5463796A/ja active Pending
- 1978-06-09 DK DK257378A patent/DK257378A/da not_active Application Discontinuation
- 1978-06-09 CA CA305,110A patent/CA1109791A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5463796A (en) | 1979-05-22 |
| AU521002B2 (en) | 1982-03-11 |
| DE2824742A1 (de) | 1979-02-15 |
| GB1584129A (en) | 1981-02-04 |
| AU3692778A (en) | 1979-12-13 |
| FR2394088B1 (enrdf_load_stackoverflow) | 1985-01-25 |
| DE2824742C2 (enrdf_load_stackoverflow) | 1989-08-31 |
| DK257378A (da) | 1978-12-11 |
| CA1109791A (en) | 1981-09-29 |
| SE7806400L (sv) | 1978-12-11 |
| FR2394088A1 (fr) | 1979-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4225575A (en) | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system | |
| US4197287A (en) | Method and apparatus for performing in nitro clinical diagnostic tests using a solid phase assay system having special utility for use with automatic pipetting equipment | |
| SE446666B (sv) | Forfarande och anordning for bestemning av en rorlig komponent i ett i en behallare infort vetskeprov, varvid denna komponent reagerar med immobiliserad komponent applicerad pa en matris med fenliknande utsprang | |
| US4305924A (en) | Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system | |
| US4244694A (en) | Reactor/separator device for use in automated solid phase immunoassay | |
| CA1149279A (en) | Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system | |
| EP0335244B1 (en) | Solid-phase analytical device and method for using same | |
| US4948726A (en) | Enzyme immunoassay based on membrane separation of antigen-antibody complexes | |
| EP0217403A2 (en) | Solid-phase analytical device and method for using same | |
| JPS5925461B2 (ja) | 免疫試験および酵素反応に使用する形成片およびその形成片による測定方法 | |
| WO1993015230A1 (en) | Calibration reagents for semi-quantitative binding assays and devices | |
| JPS596390B2 (ja) | 実験分析装置 | |
| US4317810A (en) | Waffle-like matrix for immunoassay and preparation thereof | |
| US4356260A (en) | Enzymatic indicator system | |
| US4962047A (en) | Mixing and separating solid phase supports by pressure variation | |
| US4708932A (en) | Method and device for biospecific affinity reactions | |
| US6410251B2 (en) | Method for detecting or assaying target substance by utilizing oxygen electrode | |
| US4425320A (en) | Method and apparatus for carrying out solid phase in vitro diagnostic assays | |
| JPS59501836A (ja) | 生物物質を赤血球吸着によつて検出および測定する方法 | |
| EP0031993A1 (en) | Improved method and apparatus for carrying out solid phase in vitro diagnostic assays | |
| EP0327786A1 (en) | Method and apparatus for carrying out chemical or biochemical reactions in porous carrier phases | |
| AU7255594A (en) | Water soluble polymers for use in immunoassays and dna hybridization assays | |
| WO1990001167A1 (en) | Porous support system for the immobilization of immunoassay components and assays performed therewith | |
| JPH04208836A (ja) | 反応容器キット | |
| JP2000146970A (ja) | 免疫学的測定方法及び免疫学的測定装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 7806400-3 Effective date: 19870915 Format of ref document f/p: F |